Cargando…

A review of flash glucose monitoring in type 2 diabetes

BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, Uni...

Descripción completa

Detalles Bibliográficos
Autores principales: Krakauer, Marcio, Botero, Jose Fernando, Lavalle-González, Fernando J., Proietti, Adrian, Barbieri, Douglas Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035716/
https://www.ncbi.nlm.nih.gov/pubmed/33836819
http://dx.doi.org/10.1186/s13098-021-00654-3
_version_ 1783676758098182144
author Krakauer, Marcio
Botero, Jose Fernando
Lavalle-González, Fernando J.
Proietti, Adrian
Barbieri, Douglas Eugenio
author_facet Krakauer, Marcio
Botero, Jose Fernando
Lavalle-González, Fernando J.
Proietti, Adrian
Barbieri, Douglas Eugenio
author_sort Krakauer, Marcio
collection PubMed
description BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. CONCLUSION: T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits.
format Online
Article
Text
id pubmed-8035716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80357162021-04-12 A review of flash glucose monitoring in type 2 diabetes Krakauer, Marcio Botero, Jose Fernando Lavalle-González, Fernando J. Proietti, Adrian Barbieri, Douglas Eugenio Diabetol Metab Syndr Review BACKGROUND: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. MAIN BODY: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. CONCLUSION: T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits. BioMed Central 2021-04-09 /pmc/articles/PMC8035716/ /pubmed/33836819 http://dx.doi.org/10.1186/s13098-021-00654-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Krakauer, Marcio
Botero, Jose Fernando
Lavalle-González, Fernando J.
Proietti, Adrian
Barbieri, Douglas Eugenio
A review of flash glucose monitoring in type 2 diabetes
title A review of flash glucose monitoring in type 2 diabetes
title_full A review of flash glucose monitoring in type 2 diabetes
title_fullStr A review of flash glucose monitoring in type 2 diabetes
title_full_unstemmed A review of flash glucose monitoring in type 2 diabetes
title_short A review of flash glucose monitoring in type 2 diabetes
title_sort review of flash glucose monitoring in type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035716/
https://www.ncbi.nlm.nih.gov/pubmed/33836819
http://dx.doi.org/10.1186/s13098-021-00654-3
work_keys_str_mv AT krakauermarcio areviewofflashglucosemonitoringintype2diabetes
AT boterojosefernando areviewofflashglucosemonitoringintype2diabetes
AT lavallegonzalezfernandoj areviewofflashglucosemonitoringintype2diabetes
AT proiettiadrian areviewofflashglucosemonitoringintype2diabetes
AT barbieridouglaseugenio areviewofflashglucosemonitoringintype2diabetes
AT krakauermarcio reviewofflashglucosemonitoringintype2diabetes
AT boterojosefernando reviewofflashglucosemonitoringintype2diabetes
AT lavallegonzalezfernandoj reviewofflashglucosemonitoringintype2diabetes
AT proiettiadrian reviewofflashglucosemonitoringintype2diabetes
AT barbieridouglaseugenio reviewofflashglucosemonitoringintype2diabetes